The pharmaceutical company Shionogi, which is developing a COVID-19 vaccine, plans to launch large-scale clinical trials to confirm efficacy in Southeast Asia with the cooperation of Vietnam and other countries. Shionogi is planning to conduct clinical trials with 30,000 participants. It aims to transfer production technologies to such countries and contribute to the supply of vaccines in Asia.
Shionogi is in negotiations with other Southeast Asian countries as well. The Japanese government is rushing to develop and put into practical use a domestically produced vaccine. The creation of a clinical trial network in Asia is expected to accelerate the development. (Abridged)